PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

PetMed (PETS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.18. This compares to earnings of $0.13 per share a year ago.

PetMed (PETS) Reports Break-Even Earnings for Q2

PetMed Express, Inc. (NASDAQ:PETS ) Q2 2024 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Brian Prenoveau - MZ Group, IR Matt Hulett - CEO and President Christine Chambers - CFO Conference Call Participants Ryan Meyers - Lake Street Capital Operator Good afternoon, everyone, and thank you for joining the PetMed Express Second Quarter Earnings Conference Call. My name is Shamali, the operator for today's call.

PetMed Express, Inc. (PETS) Q2 2024 Earnings Call Transcript

DELRAY BEACH, Fla. , Oct. 30, 2023 /PRNewswire/ -- PetMed Express, Inc. (NASDAQ: PETS)("PetMeds" or "Company"), Your Trusted Pet Health Expert™, today announced its financial results for its second quarter ended September 30, 2023.

PetMeds® Announces Its Second Quarter Financial Results

DELRAY BEACH, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (Nasdaq: PETS) (the “Company”), Your Trusted Pet Health ExpertTM will hold a conference call on Monday, October 30, 2023 at 4:30pm Eastern time to discuss its financial results for the fiscal second quarter ended September 30, 2023. Financial results will be issued in a press release prior to the call.

PetMed Express, Inc. Sets Fiscal Second Quarter 2024 Earnings Call

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

PetMeds (PETS) to Advance Pet Care With New Collaboration

Dog and cat owners can now choose pet insurance through PetMeds® Insurance Services, making it easier and more cost-effective to plan for accidents & illnesses and avoid unexpected vet bills. DELRAY BEACH, Fla.

PetMeds® Teams Up with Pumpkin® to Help Make Pet Care Simple and Affordable

PetMed Express faces challenges from larger competitors and declining profitability. The company has a new management team and has made strategic investments, such as partnerships and acquisitions. These investments have led to positive revenue growth, but challenges remain, including high expenses and negative operating margin.

PetMed Express Still A 'Sell,' But There Are Hopes For A Turnaround

DELRAY BEACH, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health ExpertTM, today announced its participation at the following investor conferences throughout September. Matt Hulett, CEO, and Christine Chambers, CFO, will be presenting and available for one-on-one meetings throughout each conference.

PetMed Express Announces Upcoming Conference Participation

Chewy

Freshpet

Petco Health and Wellness

Pet care stocks are not exciting, and they are low growth, but they offer significant returns for investors over the long. Takeaways from the sector include growth driven by secular tailwinds and supported by the consumer shift to consumables and services.

One of these 5 Pet Care Stocks Can Be the Next Short Squeeze

Everyone wants to get in early, but there's such a thing as buying too early. If you think a stock has promise, that doesn't mean you should buy immediately; you may find yourself in the situation of trying to catch the proverbial falling knife.

PetMed Express: A Stock To Watch For A Potential Turnaround

Start Time: 16:30 January 1, 0000 5:05 PM ET PetMed Express, Inc. (NASDAQ:PETS ) Q1 2024 Earnings Conference Call July 31, 2023, 16:30 PM ET Company Participants Matt Hulett - CEO and President Christine Chambers - CFO Brian Prenoveau - MZ Group, IR Conference Call Participants Ryan Meyers - Lake Street Capital Markets Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express First Quarter Earnings Conference Call. My name is Camilla, and I will be the operator for today's call.

PetMed Express, Inc. (PETS) Q1 2024 Earnings Call Transcript

PetMed (PETS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.14 per share a year ago.

PetMed (PETS) Reports Break-Even Earnings for Q1

DELRAY BEACH, Fla., July 31, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) (“PetMeds” or “Company”), Your Trusted Pet Health Expert™, today announced its financial results for its first quarter ended June 30, 2023.

PetMeds® Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

PetMed Express shares have returned a loss of 27.7% over the past 5 ½ months, however, the shares are reasonably cheap and the dividend yield is attractive. Despite sales being down by $16.6 million compared to the previous year, the company remains profitable with a strong balance sheet and cash from operations spiking by $9.3 million. The stock is recommended to investors who can tolerate volatility to buy shares at current prices, as the business is expected to provide decent income even if the business goes flat.

PetMed Express: I'd Take That Medicine (Rating Upgrade)

Kellogg

Walgreens

Kellogg is in the middle of a company revamp that should leave investors with a growth-focused business. Walgreens is working to integrate healthcare services into its pharmacy model.

3 Stocks to Buy Now That Are Yielding 3.5% to 8.8%

Blue Apron

Electrameccanica

As we embrace the heat of July, it's time to break down the ice around the chilling prospect of a July stock crash. The volatility in the financial markets means investors have to navigate a minefield of potential stock pitfalls.

3 Sorry Stocks to Sell in July Before It's Too Late

AMC Entertainment

Beyond Meat

GameStop

Mullen Automotive

Opendoor

Wynn Resorts

For investors, knowing when to cut ties with dead-end stock picks is always a challenge. It's easy to remain idle in the hope that a given weak investment will suddenly turn positive.

7 Dead-End Stocks to Sell Before They Dive

Ardmore Shipping

Nordic American Tankers

In general, dividend stocks are associated with blue-chip names that have a low-beta and are worth holding for the long term. However, there are several attractive high dividend small-cap stocks that offer potential for high total returns.

3 High-Dividend Small-Cap Stocks to Snag Now

Bitfarms Ltd

Devon Energy

Lucid Group

Altria

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

5 Second-Rate Stocks to Sell While You Still Can

Icahn Enterprises

Dividend payments can be both a blessing and a curse for investors. On the positive side, dividends reward stockholders with profit sharing.

3 Dangerous Dividend Stocks to Avoid at All Costs in June

Proshares Pet Care ETF

The recent impressive earnings report from Chewy, the online pet-products retailer, may ignite investor optimism in the segment and its pure-play ETF PETS.

Time for Pet ETF on Upbeat Earnings from Chewy?

DELRAY BEACH, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert™, today announced its participation at the RBC Capital Markets Consumer Day, which is being held on June 8th, 2023, at the Lotte NY Palace Hotel.

PetMed Express to Present at the RBC Capital Markets Consumer Day

Big Lots

Cato

Deciding which dividend stocks to sell can be difficult. Dividend stocks hold a special place in the hearts of investors.

3 Dividend Stocks to Sell Before They Cut Their Payouts

PetMed Express, Inc. (NASDAQ:PETS ) Q1 2022 Earnings Conference Call July 26, 2021 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Gian Fulgoni - Chairman of the Board Conference Call Participants Ben Rose - Battle Road Research Erin Wright - Credit Suisse Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the 1-800-PetMeds Conference Call to Review the Financial Results for the First Fiscal Quarter ended on June 30, 2021. At the request of the Company, this conference call is being recorded.

PetMed Express, Inc. (PETS) Q1 2022 Results - Earnings Call Transcript

PetMed Express, Inc. (NASDAQ:PETS ) Q1 2023 Earnings Conference Call July 25, 2022 4:30 PM ET Corporate Participants Matthew Hulett - President and Chief Executive Officer Bruce Rosenbloom - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the PetMeds Conference Call to Review the Financial Results for the First Fiscal Quarter Ended June 30, 2022. At the request of the company, this conference call is being recorded.

News for PetMed Express Stock (PETS)